RxDoctor Payments Data

Zachary Smith, NP

Nurse Practitioner · Auburn, NYNPI 1063126522

Payments from drug & device makers

$8,029in general payments, 2019–2025

Across 422 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$722
  • Regeneron Healthcare Solutions, Inc.$702
  • Johnson & Johnson$669
  • Incyte Corporation$623
  • E.r. Squibb & Sons, L.L.C.$586
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$7,36392%
  • Education$6668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,029 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$79,403
Medicare patients
444
Services billed
1,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SotyktuDeucravacitinib12$109,247
OtezlaApremilast14$100,358
Dupixent PenDupilumab18$66,590
Tacrolimus71$7,520
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc37$2,054
Metronidazole41$1,913
Triamcinolone Acetonide100$1,702
Minocycline Hcl27$1,412
Clobetasol Propionate33$1,360
Azelaic Acid13$1,293
Tretinoin14$1,093
Ketoconazole62$1,015
Betamethasone Dipropionate11$913
Imiquimod21$827
Clindamycin Phosphate18$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$586$109,24712 claims
AmgenOtezla$254$100,35814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Auburn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →